

Rilevanza clinica e aspetti medico-legali delle interazioni tra farmaci
DOI: https://doi.org/10.7175/pmeal.v6i2.291
Abstract
[Clinical relevance and medical legal aspects of drug-drug interactions]
Drug-drug interactions (DDIs) are an important issue of clinical pharmacology. A drug interaction occurs when the amount or the action of a drug is altered by the administration of another drug or multiple drugs. The result of a DDI can be the onset of an adverse drug reaction (ADR), the lack or the reduction of efficacy or the increase of a pharmacological effect. Apart from pharmaceutical interactions, DDIs are generally classified as pharmacokinetic or pharmacodynamic, according to the underlying mechanism. The majority of known DDIs involve the drug metabolism. The main risk factors for DDIs are age, polypharmacy, self-medication, concomitant diseases, narrow therapeutic range and dosage. In the literature most of the studies on DDIs focused on potential interactions and most data about the epidemiology of actual DDIs are related to the out-inpatient settings with different incidences. In general the incidence of actual DDIs is lower than that of potential ones, however DDIs represent a significant proportion of ADRs, since the absolute number of patients involved is high. The use of specific suggestions and recommendations could be effective in the reduction of ADRs from DDIs.
Parole chiave
Drug-drug interactions; Adverse drug reactions; Clinical risk
Riferimenti bibliografici
- Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-50
- Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-6
- Viktil KK, Blix HS, Moger TA, et al. Polypharmacy as commonly define is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 2007; 63: 187-95
- May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977; 22: 322-8
- Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14: 447-50
- Hovstadius B, Hovstadius K, Astrand B, et al. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol 2010; 10: 16
- Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-51
- Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 337-44
- Fialová D, Topinková E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293: 1348-58
- Gupta S, Rappaport HM, Bennett LT. Polypharmacy among nursing home geriatric Medicaid recipients. Ann Pharmacother 1996; 30: 946-50
- Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996; 44: 944-8
- Lindley CM, Tully MP, et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992; 21: 294-300
- Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38: 666-71
- Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25: 343-55
- Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009; 4: e4439
- Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician 2000; 61: 1745-54
- Regal RE, Ong Vue C. Drug interactions between antibiotics and selected maintenance medications: seeing more clearly through the narrow therapeutic window of opportunity. Consult Pharm 2004; 19: 1119-28
- de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005; 46: 262-73
- Wilting I, Movig KL, Moolenaar M, et al. Drug-drug interactions as a determinant of elevated lithium serum levels in daily clinical practice. Bipolar Disord 2005; 7: 274-80
- Tyler T. Drug interactions in metastatic breast cancer. J Oncol Pharm Pract 2011; 17: 236-45
- Ma TK, Lam YY, Tan VP, et al. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol 2011; 72: 697-706
- Baxter K. Stockley’s Drug Interactions. Londra: Pharmaceutical Press, 2008
- Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically
- Buurma H, De Smet PAGM, Egberts ACG. Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 2006; 29: 723-32
- Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf 2006; 29: 79-90
- Vonbach P, Dubied A, Krähenbühl S, et al. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 2008; 19: 413-20
- Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug-drug interactions in hospitalized patients. J Clin Pharmacol 2011; 51: 1043-50
- Fokter N, Mozina M, Brvar M. Potential drug-drug interactions and admissions due to drug-drug interactions in patients treate in medical departments. Wien Klin Wochenschr 2010; 122: 81-8
- Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf 2012; 11: 83-94
- Sánchez Muñoz-Torrero JF, Barquilla P, Velasco R, et al. Adverse drug reactions in internal medicine units and associated risk factors. Eur J Clin Pharmacol 2010; 66: 1257-64
- Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005; 22: 767-77
- Reis AM, Cassiani SH. Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol 2011; 67: 625-32
- Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf 2010; 33: 667-75
- Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001; 1: 167-70
- Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62
- Gerhard T. Clopidogrel and proton pump inhibitors: a clinically meaningful interaction? Pharmacoepidemiol Drug Saf 2011; 20: 214-8
- Fernando H, Dart AM, Peter K, et al. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 2011; 105: 933-44
- Fontes-Carvalho R, Albuquerque A, et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol 2011; 23: 396-404
- Close SL. Clopidogrel pharmacogenetics: metabolism and drug interactions. Drug Metabol Drug Interact 2011; 26: 45-51
- Cassazione penale, sez. VI, sentenza n. 13315 del 31 marzo 2011
- Cassazione civile, sez III, sentenza n. 364 del 15 gennaio 1997
- Cassazione civile, sez. III, sentenza n. 2847 del 9 febbraio 2010
- Cassazione civile, sez. III, sentenza n. 589 del 22 gennaio 1999
- Cassazione penale, sez. III, sentenza n. 8875 del 8 settembre1998
- Cassazione penale, sez. IV, sentenza n. 46586 del 1 dicembre 2004 (Ud 28.10.2004)
- Cassazione penale, sez. unite, sentenza n. 30328 del 11 settembre 2002
- Smithburger PL, Buckley MS, Bejian S, et al. A critical evaluation of clinical decision support for the detection of drug-drug interactions. Expert Opin Drug Saf 2011; 10: 871-82
Statistiche
Abstract: 688 visualizzazioniHTML: 3152 visualizzazioni
PDF: 7 visualizzazioni
Refback
- Non ci sono refbacks, per ora.
Copyright (c) 2012